Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-12-04 | New | $79,999,999 | $79,999,999 | Equity Only | 06b | SEC link |
| 2020-04-08 | New | $11,000,000 | $11,000,000 | Debt Only | 06b | SEC link |
| 2018-08-13 | Amended | $10,000,000 | $0 | Equity Only | 06b | SEC link |
| 2017-08-14 | New | $10,000,000 | $10,000,000 | Equity Only | 06b | SEC link |
| 2016-06-14 | New | $20,000,017 | $20,000,017 | Equity Only | 06b | SEC link |
| 2015-09-11 | New | $40,000,000 | $40,000,000 | Equity Only | 06b | SEC link |
| 2014-10-08 | New | $10,644,244 | $10,644,244 | Equity Only | 06b | SEC link |
| 2012-09-10 | New | $20,890,000 | $20,890,000 | Equity Only | 06 | SEC link |
| Name | Role |
|---|---|
| Kamil Ali Jackson | Executive |
| Kevin Balthaser | Executive |
| Richard A. Bierly | Director |
| Albert Cha | Director |
| Hugh Davis | Director, Executive |
| Brett Fair | Executive |
| David Gordon | Executive |
| Maxine Gowen | Director |
| William Humphries | Director |
| James Loerop | Executive |
| Anand Mehra | Director |
| Vincent Milano | Director |
| Christopher Molineaux | Director |
| Joseph Monahan | Executive |
| Ketan Patel | Director |
| Christopher Powala | Executive |
| Andrew Powell | Director |
| Bryan Reasons | Director |
| Frank Ruffo | Executive |
| Andrew Schiff | Director |
| Stuart Shanler | Executive |
| Steven A. Tullman | Director |
| Stephen A. Tullman | Director |
| Neal Walker | Director, Executive |